Novel Herbal Therapy For Men At High Risk Of Prostate Cancer: Results Of Phase I Trial

Main Category: Prostate / Prostate Cancer
Also Included In: Clinical Trials / Drug Trials;  Preventive Medicine
Article Date: 25 May 2009 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (2 votes)

Healthcare Prof:4 stars

4 (1 votes)


Results of a phase I clinical trial of a novel herb-based therapeutic called Zyflamend have demonstrated that the therapy is associated with minimal toxicity and no serious adverse events in men at high-risk for developing prostate cancer.

The new findings, led by researchers from the Center for Holistic Urology at Columbia University Medical Center and NewYork-Presbyterian Hospital/Columbia, are published in the current issue of the Journal of the Society for Integrative Oncology.

In the study, 23 men ages 40-75 years-old who were diagnosed with high-grade prostatic intraepithelial neoplasia (HGPIN) at biopsy, lesions that indicate an increased risk of developing prostate cancer, were admitted into this prospective clinical trial, in order to determine the safety and tolerability of Zyflamend when administered orally for 18-months, either alone or along with various dietary supplements.

"Since we know that men with HGPIN have an increased risk for developing prostate cancer, new strategies formulated to decrease cancer risk, prevent or delay surgery, and improve quality of life, will be greatly beneficial for these men," said Aaron E. Katz, M.D., senior author of the study. He is associate professor of urology at Columbia University College of Physicians and Surgeons, director of the Center of Holistic Urology at Columbia University Medical Center and a urologist at NewYork-Presbyterian/Columbia.

Basic science studies have indicated that Zyflamend may have an anti-inflammatory mechanism of action and the agent has been shown to decrease prostate cancer proliferation in cell culture.

"Our results confirm that Zyflamend, in a dose of three times daily for up to 18-months, was well tolerated," said Jillian L. Capodice, M.S., director of the Acupuncture Research and Integrative Clinical Service of the Department of Urology's Center for Holistic Urology, at Columbia University College of Physicians and Surgeons.

Prostate cancer is a cancer that forms in tissues of the prostate (a gland in the male reproductive system found below the bladder and in front of the rectum). Prostate cancer usually occurs in older men. The National Cancer Institute estimates that in 2009 there will be 192,280 new cases of prostate cancer diagnosed and 27,360 deaths attributed to prostate cancer in the United States.

Source:
Elizabeth Streich
Columbia University Medical Center

Article adapted by Medical News Today from original press release.
Visit our prostate / prostate cancer section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Elizabeth Streich. "Novel Herbal Therapy For Men At High Risk Of Prostate Cancer: Results Of Phase I Trial." Medical News Today. MediLexicon, Intl., 25 May. 2009. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/151212.php>

APA
Elizabeth Streich. (2009, May 25). "Novel Herbal Therapy For Men At High Risk Of Prostate Cancer: Results Of Phase I Trial." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/151212.php.

Please note: If no author information is provided, the source is cited instead.


Prostate / Prostate Cancer

Most Popular Articles



Follow Our Prostate News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Prostate / Prostate Cancer Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »